PDPN and ganglioneuroma: Interesting, only nonneutralizing pre-GN(GP38)-specific mAbs, known as mAb-13G8, efficiently protected IFNAR−/− mice, and IFN-I activity blocked mice.624 These findings suggested that GP38 is a potential target for CCHFV immunotherapy and demonstrated the role of ADCC and complement-mediated functions in protection against CCHF.625 However, this protection seems to be strain-limited, as passive protection by mAb-13G8 against heterologous CCHFV strains is poor.